MOTS Motus GI Holdings

Motus GI Announces the Passing of Independent Director Dr. Sam Nussbaum

Motus GI Announces the Passing of Independent Director Dr. Sam Nussbaum

FORT LAUDERDALE, Fla., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company") announced with profound sadness that Samuel R. Nussbaum, MD, an independent director on the Company’s board of directors, passed away on September 23, 2021. Dr. Nussbaum had proudly served on the Company’s board of directors since 2016, where he was a member of the compensation, and nominating and corporate governance committees.

“Sam served our Board with great commitment. He was an outstanding director, leader, and mentor, as well as a friend to all of us at Motus GI. We will miss him dearly and extend our deepest condolences to the entire Nussbaum family,” commented Tim Moran, Director and Chief Executive Officer at Motus GI.

David Hochman, Chairman of the Board, stated, “We are deeply saddened by the loss of a truly special human being. Sam was a person of the highest qualities, passionately committed to medical innovation and the improvement of healthcare delivery and outcomes. All of his work and interactions were guided by his love of people and passion for living. We were very fortunate to have the benefit of his service on our board of directors for the last five years. We will miss him greatly and his family is in our thoughts and prayers.”

Dr. Nussbaum was a highly accomplished senior executive with extensive medical and business experience across the healthcare and life sciences industries. For more than 16 years, he served as the Executive Vice President, Clinical Health Policy, and Chief Medical Officer of Anthem, Inc., where he was responsible for annual health care expenditures through business units focused on care management, health improvement, and provider network contracting. Most recently, Dr. Nussbaum spent the last five years as an influential strategic consultant for EBG Advisors, the consulting arm for Epstein Becker and Green, where he advised life science companies, health care systems, and provider organizations. Dr. Nussbaum also served as a Senior Advisor to Sandbox Industries, a venture fund, and the Ontario Teachers’ Pension Fund. Dr. Nussbaum earned his BA from New York University and his MD from Mount Sinai School of Medicine. He trained in internal medicine at Stanford University and Massachusetts General Hospital and in endocrinology at Harvard Medical School and Massachusetts General Hospital.

About Motus GI

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit  and connect with the Company on ,  and .

Investor Contact:

Bob Yedid

LifeSci Advisors

(646) 597-6989



EN
28/09/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Motus GI Holdings

 PRESS RELEASE

Motus GI Reports First Quarter 2024 Financial Results and Provides Cor...

Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update Successfully ramped up limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system; Doubled the number of active Pure-Vu System customers ordering disposable sleeves with 100% of onboarded customers using Pure-Vu independently Appointed well-known investment bank to identify and evaluate strategic alternatives aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder value FORT LAUDERDALE, Fla., May 14, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, In...

 PRESS RELEASE

Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results a...

Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update Initiated limited U.S. commercial launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system, including successful UGI procedures at several leading hospital systemsThe Company is engaged in the process to seek strategic partnerships aimed at accelerating commercialization of the Pure-Vu System and maximizing stockholder valueRecent exercise of certain outstanding warrants provided infusion of $2.7M in gross proceeds to the Company, which extended its cash runway into the fourth quarter of 2024 ...

 PRESS RELEASE

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Millio...

Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds FORT LAUDERDALE, Fla., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (Nasdaq: MOTS, or “Motus” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that it has entered into a definitive agreement for the immediate exercise of an outstanding Series B common stock purchase warrant held by an institutional investor to purchase an aggregate of 2,933,334 shares of the Company’s common stock for gross proceeds to the Company of ...

 PRESS RELEASE

Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by ...

Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.” “We are pleased to announce further strengthening our IP po...

 PRESS RELEASE

Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024...

Motus GI Holdings, Inc. Announces Adjournment of the February 16, 2024 Special Meeting of Stockholders FORT LAUDERDALE, Fla., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the Company”) (NASDAQ: MOTS), today announced that its special meeting of stockholders held on February 16, 2024 (the “Special Meeting”) was convened and then adjourned, without conducting any business, in order to provide stockholders additional time within which to vote on the proposal described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission (the “SEC”) on J...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch